Drug Type Immune cell therapy |
Synonyms- |
Target- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mantle-Cell Lymphoma | Phase 2 | US | 10 Oct 2017 | |
Recurrent Indolent Non-Hodgkin Lymphoma | Phase 2 | US | 10 Oct 2017 | |
Refractory Indolent Adult Non-Hodgkin Lymphoma | Phase 2 | US | 10 Oct 2017 | |
Plasma Cell Leukemia | Phase 2 | US | 10 Jun 2013 | |
Ependymoma | Phase 1 | US | 17 Mar 2015 | |
Medulloblastoma | Phase 1 | US | 17 Mar 2015 | |
Acute Biphenotypic Leukemia | Phase 1 | US | 03 May 2013 | |
Chronic phase chronic myeloid leukemia | Phase 1 | US | 03 May 2013 | |
Refractory Small Lymphocytic Lymphoma | Phase 1 | US | 03 May 2013 | |
Short Stature, Idiopathic, X-Linked | Phase 1 | US | 03 May 2013 |
Phase 2 | 22 | Lenalidomide+Autologous Hematopoietic Stem Cell Transplantation+Etoposide+Cord Blood-derived Expanded Allogeneic Natural Killer Cells+Carmustine+Melphalan+Filgrastim+Rituximab+Cytarabine | yizqltgubx(kchpcmebsm) = pbhewnalsj vwihebgcyo (ruyengxfvv, mlphljkpty - mwnguxnsgu) View more | - | 16 Feb 2023 |